Melinta Therapeutics reports that John H. Johnson has agreed to become the permanent chief executive officer of Melinta. Mr. Johnson is a director of Melinta and has served as interim CEO of the Company since October 22 … more

Separately, Melinta reports it has received a commitment from Vatera Healthcare Partners LLC and its affiliates for a convertible loan facility in the amount of up to of $135 million, with the option to be converted into preferred shares at an exercise price of $1.60 per share, representing a 39 percent premium to the Company’s closing share price on December 18 … more